Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for chronic kidney disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Interventions for improving sleep quality in people with chronickidneydisease. Sleep disorders are commonly experienced by people with chronickidneydisease (CKD). Several approaches for improving sleep quality are used in clinical practice including relaxation techniques, exercise, acupressure, and medication.To assess the effectiveness and associated adverse events of interventions designed to improve sleep quality among adults and children with CKD including people with end-stage kidney (...) disease (ESKD) treated with dialysis or kidney transplantation.We searched the Cochrane Kidney and Transplant Register of Studies up to 8 October 2018 with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.We included randomised controlled trials (RCTs) or quasi-randomised RCTs
Preterm birth and risk of chronickidneydisease from childhood into mid-adulthood: national cohort study. To investigate the relation between preterm birth (gestational age <37 weeks) and risk of CKD from childhood into mid-adulthood.National cohort study.Sweden.4 186 615 singleton live births in Sweden during 1973-2014.Gestational age at birth, identified from nationwide birth records in the Swedish birth registry.CKD, identified from nationwide inpatient and outpatient diagnoses through 2015 (...) males and females and did not seem to be related to shared genetic or environmental factors in families.Preterm and early term birth are strong risk factors for the development of CKD from childhood into mid-adulthood. People born prematurely need long term follow-up for monitoring and preventive actions to preserve renal function across the life course.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com
Atrasentan and renal events in patients with type 2 diabetes and chronickidneydisease (SONAR): a double-blind, randomised, placebo-controlled trial. Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes.We did this double-blind, randomised, placebo-controlled trial (...) occurred in 47 (3·5%) of 1325 patients in the atrasentan group and 34 (2·6%) of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85-2·07]; p=0·208). 58 (4·4%) patients in the atrasentan group and 52 (3·9%) in the placebo group died (HR 1·09 [95% CI 0·75-1·59]; p=0·65).Atrasentan reduced the risk of renal events in patients with diabetes and chronickidneydisease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists
2019LancetControlled trial quality: predicted high
Veverimer versus placebo in patients with metabolic acidosis associated with chronickidneydisease: a multicentre, randomised, double-blind, controlled, phase 3 trial. Patients with advanced chronickidneydisease lose the capacity to fully excrete endogenous acid, resulting in chronic metabolic acidosis that increases the risk of disease progression and causes muscle catabolism and bone resorption. Veverimer, a non-absorbed, counterion-free, polymeric drug, selectively binds and removes (...) participants were patients aged 18-85 years with non-dialysis-dependent chronickidneydisease (estimated glomerular filtration rate of 20-40 mL/min per 1·73 m2) and metabolic acidosis (serum bicarbonate concentration of 12-20 mmol/L). Patients were randomly assigned (4:3) to veverimer 6 g/day or placebo for 12 weeks while they consumed their typical diet. Both drugs were taken as oral suspensions in water with lunch. Randomisation was done by study site personnel with a computer-generated randomisation
2019LancetControlled trial quality: predicted high
Patiromer (Veltassa) - for the treatment of hyperkalemia in adults with chronickidneydisease Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs
). The remaining studies considered different populations. One study included people with chronicrenal insufficiency (mild to severe CKD), one study assessed people with CKD and kidney transplant patients, and one study included only people with IgA nephropathy. Four studies assessed ACR and PCR by using both tests to predict proteinuria at baseline, and then comparing these findings with long-term clinical outcomes. Outcomes measured varied between studies, but included all-cause mortality and kidneydisease (...) Albumin:creatinine ratio testing in the assessment and/or identification of proteinuria in people with chronickidneydisease or primary hypertension Page 1 of 6 TER005 December 2018 Topic Exploration Report Topic explorations are designed to provide a high-level briefing on new topics submitted for consideration by Health Technology Wales. The main objectives of this report are to: 1. Inform discussions on new topics received by HTW. 2. Determine the quantity and type of evidence available
General medicine: Uncertainty surrounds anticoagulation risks and benefits in patients with chronickidneydisease with atrial fibrillation Uncertainty surrounds anticoagulation risks and benefits in patients with chronickidneydisease with atrial fibrillation | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Uncertainty surrounds anticoagulation risks and benefits in patients with chronickidneydisease with atrial fibrillation Article Text Commentary General medicine Uncertainty surrounds anticoagulation risks and benefits in patients with chronickidneydisease with atrial fibrillation David Massicotte-Azarniouch 1 , Manish M Sood 1 , 2
disease. Early identification and management of chronickidneydisease in adults in primary and secondary care [ ]. This CKS topic covers the identification and management of chronickidneydisease in adults. This CKS topic does not cover the diagnosis or management of acute kidney injury (AKI), or the detailed management of complications of chronickidneydisease, such as renal anaemia and mineral and bone disorder. There are separate CKS topics on , , , , and . The target audience for this CKS topic (...) . Cardiovascular disease. See the CKS topics on , , , , and for more information. Obesity with metabolic syndrome. Obesity alone is not a risk factor for CKD. See the CKS topics on and for more information. [ ; ; ; ; ; ] Prevalence How common is it? The incidence and prevalence of chronickidneydisease (CKD) varies depending on the population studied, including ethnic group and socio-economic class [ ; ] . The large UK 'New Opportunities for Early Renal Intervention by Computerised Assessment' (NEOERICA
renaldisease (ESRD), often requiring dialysis or kidney transplantation , , . Most patients with chronickidneydisease die from other comorbidities before they progress to kidney failure. The outcome of many patients who go on to dialysis remains poor with 10 percent annual mortality; the overall 5 year survival rate is worse than that of most cancers . Evidence clearly indicates that control of hypertension and proteinuria can prevent or postpone kidney function decline . This underscores (...) and they often co-exist . Even if the cause seems obvious (e.g., diabetes), the possibility of a serious underlying primary renaldisorder (e.g. glomerulonephritis) must be considered in patients with: Abnormal urinalysis, (e.g. proteinuria, hematuria, cellular casts). Note: hyaline casts are normal . Rapid sustained decline in kidney function (change in eGFR > 10-15%/year) despite remedy of reversible precipitants (e.g. volume contraction, febrile illness, medications). Constitutional symptoms suggesting
activity mediates dehydration-induced renal injury . 15. Brooks DR , Ramirez-Rubio O , Amador JJ . CKD in Central America: a hot issue . 16. Jayasumana C , Gunatilake S , Senanayake P . Glyphosate, hard water and nephrotoxic metals: are they the culprits behind the epidemic of chronickidneydisease of unknown etiology in Sri Lanka? 17. Rampazzo N , Rampazzo Todorovic G , Mentler A , et al . Adsorption of glyphosate and aminomethylphosphonic acid in soils . 18. Ayoola S . Histopathological effects (...) General medicine: Heat-related chronickidneydisease mortality in the young and old: differing mechanisms, potentially similar solutions? Heat-related chronickidneydisease mortality in the young and old: differing mechanisms, potentially similar solutions? | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu
Nitric Oxide Decreases Acute Kidney Injury and Stage 3 ChronicKidneyDisease after Cardiac Surgery No medical intervention has been identified that decreases acute kidney injury and improves renal outcome at 1 year after cardiac surgery.To determine whether administration of nitric oxide reduces the incidence of postoperative acute kidney injury and improves long-term kidney outcomes after multiple cardiac valve replacement requiring prolonged cardiopulmonary bypass.Two hundred and forty-four (...) group) to 50% (nitric oxide group) (relative risk [RR], 0.78; 95% confidence interval [CI], 0.62-0.97; P = 0.014). Secondary outcomes were as follows: at 90 days, transition to stage 3 chronickidneydisease was reduced from 33% in the control group to 21% in the treatment group (RR, 0.64; 95% CI, 0.41-0.99; P = 0.024) and at 1 year, from 31% to 18% (RR, 0.59; 95% CI, 0.36-0.96; P = 0.017). Nitric oxide treatment reduced the overall major adverse kidney events at 30 days (RR, 0.40; 95% CI, 0.18-0.92
Association of ChronicKidneyDisease With Allopurinol Use in Gout Treatment Clinicians are often cautious about use of allopurinol in patients with gout when renal function declines.To assess the association of allopurinol use in gout with the risk of developing chronickidneydisease stage 3 or higher.A time-stratified propensity score-matched, population-based, prospective cohort study of individuals with newly diagnosed gout who initiated allopurinol (≥300 mg/d) compared with those who did (...) groups. Use of allopurinol of at least 300 mg/d was associated with lower risk of developing chronickidneydisease stage 3 or higher compared with nonusers, with a hazard ratio (HR) of 0.87 (95% CI, 0.77-0.97). Allopurinol initiation at less than 300 mg/d was not associated with renal function decline (HR, 1.00; 95% CI, 0.91-1.09).In this large cohort, allopurinol initiation of at least 300 mg/d was associated with a lower risk of renal function deterioration. Because allopurinol does not appear
Sonographic Venous Velocity Index Identifies Patients with ChronicKidneyDisease and Severe Diastolic Dysfunction Diagnosing cardiorenal syndrome (CRS) in patients with chronickidneydisease (CKD) continues to remain challenging in outpatient practice. In this study, we investigate whether a newly developed venous velocity ultrasound index (VVI) can differentiate between patients with CRS and patients with CKD of other cause or normal renal function (NRF).Patients with CRS (n = 30), CKD (n=30 (...) ), and NRF (n=30) were included in the study. For each patient, duplex ultrasound scans of intrarenal segmental veins were retrospectively analyzed. The VVI was calculated from the renal venous doppler curve as the ratio of the maximal positive venous velocity to the maximal negative venous velocity. Patients with CRS were compared to age-matched controls with NRF and to GFR-matched controls with CKD.The GFRs of patients with CRS and those with CKD were comparable (26.4±5 and 25.6±7 ml/min/m2
Kidney Damage Biomarkers and Incident ChronicKidneyDisease During Blood Pressure Reduction: A Case-Control Study. Whether the increased incidence of chronickidneydisease (CKD) during intensive systolic blood pressure (SBP) lowering is accompanied by intrinsic kidney injury is unknown.To compare changes in kidney damage biomarkers between incident CKD case participants and matched control participants as well as between case participants in the intensive (<120 mm Hg) versus the standard (...) in the setting of intensive SBP lowering was accompanied by decreases, rather than elevations, in levels of kidney damage biomarkers and thus may reflect benign changes in renal blood flow rather than intrinsic injury.National Institute for Diabetes and Digestive and KidneyDiseases.
combinations. 4. In most cases, combination therapy with other antihypertensive agents might be needed to reach target BP levels (Grade D). This recommendation is based on expert consensus. 5. The combination of an ACE inhibitor and ARB is not recommended for patients with nonproteinuric chronickidneydisease (Grade B). Dual renin-angiotensin system (RAS) inhibition has been shown to reduce significantly proteinuria , a surrogate endpoint for cardiovascular disease, and renal impairment in patients (...) to develop future recommendations for these patient populations. References Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood- pressure control on the progression of chronicrenaldisease. Modification of Diet in RenalDisease Study Group. N Engl J Med 1994;330:877-84. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidneydisease: long-term follow-up of the Modification of Diet in RenalDisease study. Ann Intern
Do thiazides work in patients with chronickidneydisease? Do Thiazides Work in Patients With ChronicKidneyDisease? – Clinical Correlations Search Do Thiazides Work in Patients With ChronicKidneyDisease? October 4, 2018 4 min read By Hannah Friedman Peer Reviewed It is a commonly seen scenario on the wards: a patient with a past medical history of heart failure and stage 4 chronickidneydisease presents with progressive shortness of breath and worsening lower extremity edema. The patient (...) (Stage 4-5). However, recent literature .  Recent reports estimate that 13.1% of the US population has chronickidneydisease (CKD), with 8% having at least stage 3 CKD.  These patients have a ,  and this risk worsens as the disease progresses. Thiazides and thiazide-like diuretics act on the distal convoluted tubule of the nephron, specifically on the .  This mechanism makes thiazides useful not just as antihypertensives, but also as diuretics in volume-overloaded patients. Thiazides
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with ChronicKidneyDisease: A Randomised Double-Blind Trial Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac biomarkers in people with moderate to severe chronickidneydisease are unknown.The UK HARP-III trial (United Kingdom Heart and Renal Protection-III), a randomized double-blind trial, included 414 (...) (36.7% versus 28.0%; rate ratio, 1.35; 95% CI, 0.96-1.90), and potassium ≥5.5 mmol/L (32% versus 24%, P=0.10) was not significantly different between randomized groups.Over 12 months, sacubitril/valsartan has similar effects on kidney function and albuminuria to irbesartan, but it has the additional effect of lowering blood pressure and cardiac biomarkers in people with chronickidney disease.URL: http://www.isrctn.com . Unique identifier: ISRCTN11958993.
retinopathy diabetes mellitus hypertension age >50 years childhood kidneydisease smoking obesity black or Hispanic ethnicity family history of chronickidneydisease autoimmune disorders male sex long-term use of NSAIDs Diagnostic investigations serum creatinine urinalysis urine microalbumin renal ultrasound estimation of GFR renal biopsy plain abdominal radiograph abdominal CT abdominal MRI Treatment algorithm ACUTE Contributors Authors Assistant Professor of Medicine University of Arkansas for Medical (...) is determined only by laboratory studies. Glycaemic control for diabetic nephropathy and optimisation of blood pressure are key in slowing the progression of disease. Increased risk for cardiovascular disease. Definition Chronickidneydisease (CKD), also known as chronicrenal failure, is defined by either a pathological abnormality of the kidney, such as haematuria and/or proteinuria, or a reduction in the glomerular filtration rate to <60 mL/minute/1.73 m² for ≥3 months' duration. KidneyDisease
Left Main Revascularization With PCI or CABG in Patients With ChronicKidneyDisease: EXCEL Trial The optimal revascularization strategy for patients with left main coronary artery disease (LMCAD) and chronickidneydisease (CKD) remains unclear.This study investigated the comparative effectiveness of percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery in patients with LMCAD and low or intermediate anatomical complexity according to baseline renal (...) function from the multicenter randomized EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial.CKD was defined as an estimated glomerular filtration rate <60 ml/min/1.73 m2 using the CKD Epidemiology Collaboration equation. Acute renal failure (ARF) was defined as a serum creatinine increase ≥5.0 mg/dl from baseline or a new requirement for dialysis. The primary composite endpoint was the composite of death, myocardial infarction (MI
Evans M, Grams ME, Sang Y, etÂ al., for the ChronicKidneyDisease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625â€“637 [This corrects the article DOI: 10.1016/j.ekir.2018.01.002.].